ArticleApplied biochemistry and biotechnology2026
A 3D Bioprinted dECM/CSCA/SA/NC Hybrid Scaffold for Myocardial Infarction Healing.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In recent years, the incidence of cardiovascular disease (CVD) has risen annually, among which acute myocardial infarction is a common, critical, and severe disease in clinical practice. Advances in tissue engineering and 3D printing have enabled biological scaffolds to emerge as a novel therapeutic approach for cardiac repair in AMI treatment. This study fabricated 3D-printed scaffolds using a porcine cardiac decellularized extracellular matrix (dECM)/caffeic acid-grafted chitosan (CSCA)/sodium alginate (SA)/nanoclay (NC) bioink, characterized by its physicochemical properties and cytocompatibility. Four bioink formulations with varying dECM concentrations were tested, with optimal printable parameters determined as 10% NC, 1% CSCA, and 1.5% SA. The 3D-printed sheet scaffolds exhibited abundant porous internal structures. For scaffolds 0D10N1.5SA, 0.5D10N1.5SA, 1D10N1.5SA, and 1.5D10N1.5SA, swelling rates were 220.99 ± 7.49%, 216.33 ± 8.02%, 207.43 ± 8.71%, and 202.30 ± 13.5%, respectively, while elastic moduli were 38.62 ± 2.25 kPa, 32.98 ± 2.67 kPa, 29.46 ± 1.70 kPa, and 19.68 ± 2.07 kPa. All scaffolds demonstrated good hydrophilicity and mechanical properties. In the biocompatibility test, it was observed that the number of cells on the scaffolds increased gradually with the increase in culture time. In particular, when the content of dECM increased, the number of cells also increased accordingly. More importantly, the cells could migrate into the scaffolds to form scaffold materials with biological functions. These results not only verify the excellent biocompatibility of the scaffold but also demonstrate its clear potential for applications in the development of cardiac tissue engineering scaffolds and implantable therapeutic devices following myocardial infarction.
Indexed as
Identifiers
41484745What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.